

Company Number: 211291

European Institute of Women's Health Limited
Annual Report and Financial Statements
for the financial year ended 30 June 2019

European Institute of Women's Health Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 11
Directors' Responsibilities Statement	12
Independent Auditor's Report	13 - 14
Income and Expenditure Account	15
Balance Sheet	16
Reconciliation of Members' Funds	17
Cash Flow Statement	18
Notes to the Financial Statements	19 - 21

European Institute of Women's Health Limited DIRECTORS AND OTHER INFORMATION

Directors	Sinead Hewson Karen Ritchie Hildrun Sundseth Maeve Cusack Barbra Dowling Janusz Janczukowicz Orla Sheils Nelson (Appointed 20 April 2019)
Company Secretary	Clare Manning (Resigned 30 April 2019) Hilary Murphy (Appointed 30 April 2019)
Company Number	211291
Charity Number	20035167
Registered Office	33 Pearse Street Dublin 2
Auditors	Only Audit Limited Chartered Certified Accountants & Statutory Auditors 56 Lansdowne Road Ballsbridge Dublin 4
Bankers	Bank of Ireland 2 College Green Dublin 2
Solicitors	Young & Company 2 Charleston Road Rathmines Dublin 6

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

The directors present their report and the audited financial statements for the financial year ended 30 June 2019.

Principal Activity and Review of the Business

About the European Institute of Women's Health (EIWH)

The objective of the European Institute of Women's Health (EIWH) is to promote the advancement of education and public awareness of women's and family health issues throughout Europe by conducting research, undertaking surveys, establishing and delivering training programmes, seminars and conferences on all aspects of health care.

The EIWH is a registered charity (number 20035167) and is governed by a board of directors nominated by members. Membership of the EIWH is open to individuals and organisations with an interest in women's and family health. EIWH has a membership base of individuals and organisations that contribute to the ongoing work of the EIWH. <http://www.charitiesregulatoryauthority.ie/en/cra/pages/home>

Together with its members, the EIWH works to:

- Promote lifelong health in women and their families.
- Ensure quality and equity in health policy, research, treatment and care for all.
- Draw the attention of policymakers to the obstacles that women who belong to minority and disadvantaged groups face in obtaining a desirable health status.
- Empower individuals to play an active part in their own health management.
- Promote gender-specific bio-medical and socioeconomic research that addresses sex and gender-based differences, to ensure equal access to quality prevention, treatment and care for women and their families throughout their lifespan.

The EIWH aims to reduce inequalities in health, those due to gender, age and socioeconomic status, by highlighting that sex and gender are important determinants of health. The EIWH works to improve and promote the understanding that vulnerability to, onset and progression of specific diseases vary in men and women.

The key priorities of the EIWH include:

- Prevention of chronic diseases.
- Promotion of health and well-being and combating smoking, drinking and obesity in women.
- Promoting active and healthy ageing across the lifespan and increasing healthy life years.
- Ensuring access to high quality treatment and care across an individual's lifespan.
- Ensuring safety of medicines in pregnancy and lactation.
- Highlighting sex and gender in medicines regulation and medical education.
- Promoting vaccination across the lifespan.
- Advocating for healthy pregnancies.
- Advocating for awareness of mental health issues, with a focus on managing depression.
- Advocating for sex and gender sensitive health systems.

The EIWH has an Expert Advisory Group appointed by the board which guides EIWH policies and activities.

Board Members

Hildrun Sundseth, President of the EIWH, Germany
Maeve Cusack, National Cancer Control Programme, Ireland
Barbara Dowling, University of the Arts London
Sinead Hewson, TpEBO, Netherlands
Janusz Janczukowicz, Lodz University, Poland
Karen Ritchie, INSERM, Montpellier
Orla Shiels, Trinity College, Dublin

Company Secretary, Hilary Murphy

Secretariat

Peggy Maguire, Director General
Vincent Herity, Financial Manager
Kristin Semancik, Researcher
Vanessa Moore, Researcher
Rebecca Moore, Researcher

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

Board Activity

Members of the board of the EIWH are located Europe-wide therefore a monthly meeting is hosted by teleconference and annually in person. The Annual face to face meeting took place in Brussels on the 15th of March 2019. The meeting provided the opportunity to present, review and evaluate the activity undertaken by the EIWH in the preceding 12 months as well as agree an outline of the future activity, direction and priorities for the EIWH. At this meeting, the annual report for the financial year 2017-2018 was presented and approved.

Financial Overview

One of the main objectives of the board is to ensure the sustainability of the EIWH. The main source of income for the EIWH is through EU project funding. This is supplemented from time to time by a small amount of industry funding. EIWH Treasurer Sinead Hewson, having examined the audited accounts, noted an improvement in the finances for financial year 2017-2018, compared to previous years. The board agreed to continue its focus on applying for project funding while examining opportunities to diversify.

Governance

The EIWH initiated the review of its governance code to ensure compliance with the statutory Irish Governance Code for charities.

Activity Overview 2018-2019

The EIWH takes an active and prominent role in contributing to and shaping European policy on women's health and that of their families. The EIWH is proud of its continuing partnership with and contribution to agencies including the World Health Organization (WHO), the European Medicines Agency, The EU Commission and the EU Parliament. The work of the EIWH has helped to shape health policy that affects and benefits women Europe-wide. The EIWH is wholly committed to continuing its role in promoting the importance of gender equality in health and social policy, research and care, and to ensure access to quality treatment and care for women across their life-course, regardless of their economic status.

Representation: European Medicines Agency (EMA)

Due to the UK Brexit plans to leave the European Union, the EMA moved their headquarters from London to Amsterdam. The EIWH has been a member of the Patient and Consumer Working Party (PCWP) of the European Medicines Agency for the last 20 years. This Working Party provides recommendations to EMA human scientific committees on all matters of interest to patients and citizens in relation to the safe and effective use of medicinal products. The European Medicines Agency is the European Union (EU) body responsible for the scientific evaluation and approval of medicines developed by pharmaceutical companies. The EMA centrally reviews and approves innovative medicinal products, based on the clinical trial data supplied by the applicant organisation. This approval process is strictly defined and regulated by EU legislation. Once approved, the medicinal product receives a marketing authorisation for use in the EU and European Economic Area (EEA).

Why is the work of the EMA important to women's health?

Women are some of the heaviest users of medicines, starting early with birth control pills, and across their lifespan as longevity champions. Additionally, due to women's reproductive and their caring role in society, women have a specific interest in, but also knowledge to offer about medicines use for themselves and their families.

For more information about the EMA and the Patient and Consumer Working Party: http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000017.jsp

New EMA Regulatory Strategy

EIWH contributed to the EMA consultation for the EMA Regulatory Strategy 2025, commenting on the need for EMA to consider certain vulnerable population groups such as pregnant and lactation women in the regulatory strategy, as well as older patient with several different medical conditions.

Raising the issues about Safe use of Medicines during Pregnancy and Lactation with EMA

EIWH President attended several EMA meetings to highlight the EIWH work on the Safe Use of Medicines during Pregnancy and Lactation as outlined in the EIWH Policy Brief. This issue is currently a neglected medical and public health need, as little or no information is available to pregnant and lactating women and their health professionals regarding which medicines are safe to take during this period.

Because of EIWH efforts to highlight this regulatory and societal gap in public health, the Innovative Medicines Initiative (IMI) set up the Research Consortium called "ConCEPTion". (see below)

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

Monash University

Monash University Research Project - Preconception, Pregnancy and Post-partum Health

In September 2018, EIWH participated in the Monash University Research project on *Health in Preconception, Pregnancy and Postpartum (HiPPP) Global Alliance*. Following the meeting, we contributed to the joint research paper on priorities for the prevention of maternal obesity and related pregnancy and long-term complications. The paper which contains the contribution from various world-wide health experts included the view of EIWH as representative organization from the health user/patient group has now been submitted for publication.

European Centre for Disease Control and Prevention (ECDC) -Technical Advisory Group on Vaccination uptake

EIWH continues to interact and support the European Centre for Disease Control and Prevention (ECDC) -Technical Advisory Group on Vaccination and the development of the ECDC Information portal which will be launched in 2020. The portal will provide information on vaccination to health care professionals and the general public.

ECDC Patient group representation: The Commission launched a selection procedure to appoint the representatives of non-governmental organisation representing patients at the Advisory Forum of the European Centre for Disease Prevention and Control (ECDC). The EIWH application was successful and will participate in ECDC meetings four times per year representing patient organisations.

The EU Commission Coalition for Vaccination

The EIWH was invited to attend the meeting for the creation of a Coalition for Vaccination on 4 March 2019 in Brussels. The objective of this meeting was to discuss the creation of a Coalition for Vaccination, as requested in the Council Recommendation on strengthened cooperation against vaccine preventable diseases and to reach agreement on the most appropriate structure, scope, governance and general objectives of a Coalition for Vaccination. In order to keep the discussion focused only one participant per organisation can attend.

The EIWH is a member of the Stakeholder group in the Joint Action - Vaccination

The EIWH attended a meeting on 4th of September 2018. Building on existing initiatives, the EU-JAV is developing common and durable cooperation to build concrete tools useful for EU and non-EU Member States' health authorities. Over a three-year period, the EU-JAV aims to develop tools to strengthen national responses to vaccination challenges in Europe and therefore improve population health. EU-JAV will build on the numerous existing initiatives and projects, first and foremost in Europe, while contributing to sustainability by incorporating its achievements into the health policies of European countries. To contribute to this goal, the EU-JAV will involve a wide range of stakeholders that share a common vision.

The EU-JAV proposes to address important issues, common to many countries by:

- Establishing the sustained cooperation of relevant Member State authorities;
- Defining basic principles for vaccine demand forecasting;
- Developing a concept and prototype for a data warehouse for EU-wide sharing of vaccine supply and demand data among dedicated stakeholders;
- Defining common stages and criteria for priority-setting of vaccine research and development (R&D);
- Developing a concept and prototype for a vaccine R&D priority setting framework;
- Defining structural, technical and legal specifications for data requirements for electronic vaccine registries/databases/Immunisation information systems;
- Providing a framework to cooperate on confidence from research to best practices and implementation.

Health Technology Assessment (HTA)

The EIWH is a member of the EU Commission HTA Stakeholder Pool.

On the 31st of January 2018, the Commission put forward a proposal to boost cooperation amongst EU MemberStates for assessing health technology. The EIWH welcomes the Commission proposal. Greater transparency will empower patients, by ensuring their access to information on the added clinical value of new technology that could potentially benefit them. The EIWH has prepared a draft position paper on HTA. A Sex &Gender-sensitive approach has not been included in most HTA assessments and is rarely adopted in the current HTA process. The EIWH argues that S&G considerations must be considered not only to ensure equitable practice, but also to promote effective outcomes for all patients and citizens in Europe. The consistent integration of S&G into each stage of the HTA process will improve the quality of evidence and health outcomes for all in Europe.

The EIWH was invited to a meeting together with six other NGOs with EU Health Commissioner Mr. Andriukaitis to discuss the issues around HTA. In July 2018 the EIWH was also invited to an EU Commission conference on HTA in Brussels.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

On the 16th January 2019 the EIWH attended and contributed to the first meeting of the Stakeholder Pool of the HTA Network. The Chair, **Andrzej Ryś**, welcomed participants at the meeting of the HTA Network's Stakeholder Pool and highlighted that this is an important milestone in the ongoing process of the stakeholder involvement. The two new members, EORTC – European Organisation for Research and Treatment of Cancer and ARM - Alliance for Regenerative Medicine, were introduced. Currently the Stakeholder Pool gathers 33 European umbrella organisations, including the EIWH which have been selected through an open call for expression of interest. The member organizations are grouped in four pillars representing: (1) patient/consumers; (2) providers (e.g. health care professionals and academia); (3) payers; (4) industry (both pharmaceutical and medical technologies sectors). The Chair recalled the strategic objectives of the Stakeholder Pool: (1) to contribute to the development related to HTA at EU level; (2) to ensure that the views of different stakeholders are reflected in the policy development in a balanced way; and (3) to create synergies between different stakeholders.

Launch of EIWH Manifesto October 2018

In the run up to the 2019 European Parliament elections, EIWH officially launched its EU Manifesto for Women's Health in the European Parliament on the 10th of October. The event was hosted by Ms. Deirdre Clune. Speakers included Members of European Parliament, representatives from the European Commission, World Health Organization and other key health stakeholders. The event marks the beginning of the EIWH's campaign **Healthy Women—Healthy Europe**, which profiles that Europe **can do more to** prioritise women's health in order thereby improving the health of all.

The **EU Manifesto for Women's Health** highlights some central issues in women's health and calls on the Europe to do more now. European stakeholders must work together to enact, enforce, support, protect, partner, share and research. Only through concerted, tangible, concrete and swift action can women's and their families' health be improved across the EU. The EIWH calls on the European Parliament and other stakeholders to implement the Manifesto and include women's health in the questioning of Commissioners in the new government.

The EIWH's EU **Manifesto for Women's Health and** supporting documents are available online: <https://eurohealth.ie/manifesto2018/>

World Congress in Paris on Women's Mental Health

In April 2019 EIWH, WHO and the Austrian Institute for Health jointly organised a successful workshop at the World Congress in Paris. The EIWH presentation topic was "Depression in Pregnancy". Writing a Policy Brief on Women and Depression is now one of the priorities for EIWH.

Antimicrobial Awareness Day

The EIWH participated in the discussion of the Antimicrobial Awareness Day, held by the European Centre for Disease Control (ECDC) and Prevention on 18th November 2018. The growing resistance to many antibiotics is a public health threat that has been steadily increasing in recent decades. As a result, many common infections are becoming difficult or even impossible to treat, sometimes turning a simple infection into a life-threatening condition. Antibiotics are vital in reducing the risk of complications in complex medical intervention such as hip replacements, organ transplants, cancer chemotherapy and the care of premature babies.

The EIWH partners with the ECDC annually to raise awareness of the threat through targeted media relations on Antimicrobial Awareness Day.

European Immunisation Week

The EIWH developed a key vaccination policy brief titled 'Women and Vaccination in the EU'. In support of European Immunisation Week in April 2019, the EIWH re-issued this vaccination policy brief with a press release to media. A social media campaign saw pertinent vaccination information and messages being shared daily. The aim of the campaign was to increase awareness of the importance of vaccination in preventing the spread of infectious disease which is particularly relevant at a time when vaccination participation is decreasing.

EIWH Women and Alzheimer Advisory Council and Dementia Report

The EIWH European Advisory Council on Women's and Alzheimer's Disease was formally launched on the 22nd of January 2019 with the publication of the EIWH Position paper Women and Dementia in the EU. At this meeting in the European Parliament in Brussels, EIWH also officially launched its Position Paper "*Women and Dementia in Europe: Addressing the disproportionate burden of dementia on women*".

The event was hosted by Sirpa Pietikäinen, Finnish Member of the European Parliament (MEP) and longstanding advocate of women's health issues and dementia at European and national level. Speakers included representatives from the EIWH, European Commission, European Brain Council, Eurocarers, Age Platform EU, national Alzheimer's associations and Fundació ACE. This event took place under the EIWH's campaign **Healthy Women—Healthy Europe**, which profiles that Europe can do more to prioritize women's health.

The Alzheimer's conference report highlights the disproportionate burden of Dementia on Women, both in terms of being affected by the disease themselves but also as carers of Alzheimer's family members. Members of the Alzheimer's Council spoke at the launch giving their perspective on this devastating disease.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

Women's Brain Project International Conference

The EIWH was invited to make the keynote speech at the Women's Brain Project International Conference in Zurich, on the 9th June 2019. The Presentation included information on the biological and social determinants of women's health and outlined the EIWH Manifesto "Europe Can Do More"

EU- Projects

MOPEAD IM1 H2020 project: Models of Patient Engagement for Alzheimer Disease (AD)

Objective of the project was to establish multiple key regional project sites across Europe to identify and test models of efficient earlier identification of mild AD patients, awareness of AD, memory complaints, and cognitive decline risks.

MOPEAD will establish regional hubs across five EU countries (ES, DE, NL, SE, and SL);

EIWH is task leader in WP Dissemination and participated in Partner Meetings, contributed to the Project Newsletter and to the article on Alzheimer disease.

The EIWH will complete a policy brief on Gender and Alzheimer Disease with the research starting at the beginning of 2019. The EIWH takes part in a bi-monthly TC to discuss communication issues and activities with the other partners. The EIWH provides input into infographics, including quotes and English revision, and newsletters. <https://www.imi.europa.eu/content/mopead>.

MyHealth Project

The EIWH is a partner in the project MY Health which is funded by DG Sante. The EIWH is leading the Communication and Dissemination Work package. The main aim of MyHealth is to improve the healthcare access of vulnerable immigrants and refugees newly arrived in Europe, by developing and implementing models based on know-how of a European multidisciplinary network.

During the monthly teleconferences and AGMs, EIWH ensures that communication and dissemination is considered throughout the project, including during the development of tools, reports and other activities. The EIWH works to make the public documents accessible and user friendly to encourage dissemination. The EIWH and partners have been adjusting the communication strategy throughout the project to improve dissemination moving forward.

The EIWH conducted the legal and organizational mapping of partner countries on access to health services. The results are being used as part of the base for the interactive map. This map was shared with the MigHealthCare project for use as their template as well. The map was designed to be user friendly through the application.

The EIWH disseminates project results and reports as well as publicizes project events. The EIWH advises partners when queried on communication and dissemination issues, such as how to increase the response rate of the mapping surveys. The EIWH is working with partners to identify and engage key stakeholders in order to involve diverse actors in the project and disseminate project results. The EIWH has worked with partners to identify strengths and weaknesses of communication to improve the efforts moving forward.

GO NANO project- Governing nanotechnologies through societal engagement.

The EIWH is a partner in Go Nano project. The project enables co-creation between citizens, civil society organisations, industry, researchers and policy makers across Europe to align future nanotechnologies with societal needs and concerns. GoNano aims to demonstrate how researchers can work with public and professional stakeholders to create novel suggestions for future nanotechnology products. The goal is to co-create concrete product suggestions within the areas of food, health and energy, illustrate new opportunities for innovation and develop policy recommendations. The EIWH completed a literature review on nanotechnology gender and culture. The EIWH has completed a white paper on Gender and Nano technology and contributed to several other papers relating to Nano technology.

ConcePTION – use of medication during pregnancy and lactation

ConcePTION is a large 5-year landmark Innovative Medicines (IMI-2) research project funded in part by the European Community budget and contributions from pharmaceutical companies. Its aim is to build **a pan-European ecosystem for generating, monitoring and providing robust information on medication safety in pregnancy and breast feeding.**

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, researchers and teratology networks to innovate new solutions to a long neglected public health issue.

With a shared vision that there is a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and breastfeeding, the **ConcePTION** team will work to create sustainable solutions to the problem. Through better use of existing health data from routine, daily practice together with enhanced methods to collect patient-reported data, and with new research capabilities to predict and measure maternal medication in breast milk, the team hopes to close the current information gap.

The EIWH is involved in several Work Packages and has a seat on the Management Board of ConcePTION.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

Proposals submitted:

Revised proposal TALENTED on Cervical Cancer prevention

The old proposal has been revised and is now called TALENTED has been successful in getting through the first stage. EIWH are leading the Communication Work package and are currently completing the WP outline for the co-ordinator at the French research Institute (Inserm).

TALENTED aims to create the projection model to evaluate targeted population-based interventions accounting for country-specific contextual factors such as costs, and estimate impact according to improving coverage and participation in screening among women who are hard to reach and are at increased risk for Cervical Cancer.

Proposal: ARTEMIS-Understanding causative mechanisms in co- and multi morbidities combining mental and non-mental disorders. Unfortunately, this proposal was not successful.

Proposal: Gender aspect in transport and social inclusion.

EIWH was approached by a partner in the Go Nano project, to consider taking part in a Horizon 2020 proposal on transport. The co-ordinator of the project is the Center for Innovation in Transport (CENIT) is a research group of the International Center for Numerical Methods in Engineering (CIMNE). Unfortunately, this proposal was not successful.

EIWH National Focal Points

The EIWH is working to continue linking as well as strengthening its European and national activities and has been distributing the EIWH Manifesto to national health attachés and other Member State representatives in order to increase awareness of major health and social issues that affect women in Europe.

The Institute of Public Health, Austria and Charité Germany are the first EIWH focal points and set an example of how further national focal points can be developed. The EIWH has identified further potential **focal points** and developed a terms of reference document for use in all Member States.

Consultations

- Responded EU Commission
Roadmap:European-Partnership-for-innovative-health :https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/11906-European-Partnership-for-innovative-health/feedback?p_id=5722422-
- Responded to ECDC public consultation on draft guidance for introduction of HPV vaccines in EU countries: focus on 9-valent HPV vaccine and vaccination of boys and people living with HIV
<https://www.ecdc.europa.eu/sites/portal/files/documents/hpv-public-consultation-1-April-2019.pdf>
- Responded to consultation EU Beating Cancer Roadmap.
https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12154-Europe-s-Beating-Cancer-Plan/feedback?p_id=6335574&page=34

Communications

The EIWH engages with media and the public to promote key initiatives and partnerships and to raise general awareness around major issues and conditions affecting women and their families. Outlined below is a sample of news releases issued by the EIWH in 2018 and 2019.

Social Media

The EIWH has increased its social media presence by regular tweeting.

For example: Tweeted in September, which was World Alzheimer month, Go Nano Tweets, meetings attended.

Publications - Policy Briefs

The European Institute of Women's Health generates policy briefs on many issues and makes recommendations for policy action. In keeping with the objective of the EIWH, policy briefings are developed following consultation with the Institute's network and are pertinent to women's health. Policy statements are distributed widely to stakeholders, policymakers and citizens and are available to view online at www.eurohealth.ie

The following policy briefs have been completed during this period

Gender and Health Technology Assessment (HTA)

Gender PB for MOPEAD, 2019:

https://17215c60-696c-4eb6-9adb-50cde843a50f.filesusr.com/ugd/e8882a_08fb25c1523345ed90dd6b3e32cede6b.pdf

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

Policy Briefs/position paper currently being written

Maternal Health Report
Midlife and Older Women's Health
Gender and Digital Health
Women as Carers across the life course
Gender and Nutrition

Published articles

Chronic Inequities Health Management (Politico), 2018:

<https://healthmanagement.org/c/healthmanagement/issuearticle/chronic-inequities-the-top-killer-of-women-in-europe>

Alzheimer's disease 1 , 2019: <https://www.ncbi.nlm.nih.gov/pubmed/31076376>

Alzheimer's disease , 2018: [https://alzheimersanddementiajournal.com/article/S1552-5260\(18\)31837-5/pdf](https://alzheimersanddementiajournal.com/article/S1552-5260(18)31837-5/pdf)

Gender PB for MOPEAD, 2019:

https://17215c60-696c-4eb6-9adb-50cde843a50f.filesusr.com/ugd/e8882a_08fb25c1523345ed90dd6b3e32cede6b.pdf

EIWH membership/ Advisory Roles

The EIWH will continue in its role as advisor to the following:

- European Medicines Agency (EMA): Member of Patient and Consumer Working party
- European Commission, DG SANTE: HTA Stakeholder pool
- DG SANTE: Member of the Joint Action -Vaccination Stakeholder platform
- European Centre for Disease Control and Prevention (ECDC): Formal Advisory Group Representing-Patients (Observer)
- European Centre for Disease Control and Prevention (ECDC) Technical Advisory Group on Vaccination Uptake
- European Public Health Alliance (EPHA): Board Member and former Presidency,
- European Patients Forum: Member of the Digital Advisory Group
- Member of European Federation of Pharmaceutical Industries and Associations (EFPIA) Patient/Industry Think Tank and joint Action on Vaccination
- WHO: Expert Advisor to and Member of the Expert Group on gender mainstreaming and WHO Women's Strategic Plan
- Member of BBRMI Eric, a European research infrastructure for biobanking
- Fundamental Rights Agency: Member of the Stakeholder Platform
- Co-Chair of the Department of Health (Ireland), Women's Health Task Force
- Member of the Department of Health (Ireland), Independent Patient Safety Council

Financial Results

The deficit for the financial year amounted to €(27,625) (2018 - €(14,935)).

At the end of the financial year, the company has assets of €120,850 (2018 - €131,499) and liabilities of €27,463 (2018 - €10,487). The net assets of the company have decreased by €(27,625).

Directors and Secretary

The directors who served throughout the financial year, except as noted, were as follows:

Sinead Hewson
Karen Ritchie
Hildrun Sundseth
Maeve Cusack
Barbra Dowling
Janusz Janczukowicz
Orla Sheils Nelson (Appointed 20 April 2019)

The secretary who served throughout the financial year was Clare Manning.

The company is limited by guarantee not having a share capital and therefore the directors or company secretary have no direct interest in the company.

In accordance with the Articles of Association, the directors retire by rotation and, being eligible, offer themselves for re-election.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2019

Future Developments

The directors are not expecting to make any significant changes in the nature of the business in the near future. At the time of approving the financial statements, the company is exposed to the effects of the Covid-19 pandemic, however the due to the nature of the company's activities the company has continued to operate and apply for projects and funding. In planning its future activities, the directors are aware that future funding for projects may become limited and will develop the activities of the company accordingly.

Principal risks and uncertainties

The principal risk the company is exposed to remains the availability of funding as this is dependent on external factors and is outside the control of the company. The directors consider that the principal risk in relation to funding is the outbreak of Covid-19 which has resulted in a significant slowdown in economic activity in Ireland and could impact future funding. Any such reduction in funding would impact the company's operations. The directors can not fully quantify the effects of Covid-19 at the time of approving the financial statements. The company operates solely in the Republic of Ireland, therefore is not subject to currency risk. The company does not rely on significant borrowings and has minimal exposure to interest rate risk. The company's policy is to ensure that sufficient resources are available from cash balances and cashflows to ensure that all obligations can be met as they fall due.

Post Balance Sheet Events

In the first half of 2020, the Covid-19 virus spread worldwide. In common with many other countries, the Irish government issued guidance and restrictions on the movement of people designed to slow the spread of this virus. The company put the necessary conditions in place to enable the company to continue to operate during this period. The directors are confident that the company will be fully operational once the period of restriction is lifted.

Auditors

The auditors, Only Audit Limited, (Chartered Certified Accountants & Statutory Auditors) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.

Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at 33 Pearse Street, Dublin 2.

Signed on behalf of the board

Barbara Dowling
Director

Maeve Cusack
Director

Date: _____

Date: _____

European Institute of Women's Health Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2019

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Barbara Dowling
Director

Maeve Cusack
Director

Date: _____

Date: _____

INDEPENDENT AUDITOR'S REPORT

to the Members of European Institute of Women's Health Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of European Institute of Women's Health Limited ('the company') for the financial year ended 30 June 2019 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and the related notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 30 June 2019 and of its deficit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 5 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which ISAs (Ireland) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- in our opinion, the Directors' Report has been prepared in accordance with the Companies Act 2014.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited. The financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report. The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

INDEPENDENT AUDITOR'S REPORT

to the Members of European Institute of Women's Health Limited

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: <www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf> The description forms part of our Auditor's Report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Tracey Byrne

for and on behalf of

ONLY AUDIT LIMITED

Chartered Certified Accountants & Statutory Auditors

56 Lansdowne Road

Ballsbridge

Dublin 4

Date: _____

European Institute of Women's Health Limited INCOME AND EXPENDITURE ACCOUNT

for the financial year ended 30 June 2019

	Notes	2019 €	2018 €
Income		104,623	176,967
Expenditure		<u>(132,248)</u>	<u>(191,902)</u>
Deficit for the financial year		<u>(27,625)</u>	<u>(14,935)</u>
Total comprehensive income		<u><u>(27,625)</u></u>	<u><u>(14,935)</u></u>

Approved by the board on _____ and signed on its behalf by:

Barbara Dowling
Director

Maeve Cusack
Director

European Institute of Women's Health Limited
BALANCE SHEET

as at 30 June 2019

	Notes	2019 €	2018 €
Current Assets			
Stocks	8	60,000	11,377
Cash and cash equivalents		60,850	120,122
		<u>120,850</u>	<u>131,499</u>
Creditors: Amounts falling due within one year	9	<u>(27,463)</u>	<u>(10,487)</u>
Net Current Assets		<u>93,387</u>	<u>121,012</u>
Total Assets less Current Liabilities		<u>93,387</u>	<u>121,012</u>
Reserves			
Income and expenditure account		93,387	121,012
Equity attributable to owners of the company		<u>93,387</u>	<u>121,012</u>

The financial statements have been prepared in accordance with the small companies' regime.

Approved by the board on _____ and signed on its behalf by:

Barbra Dowling
 Director

Maeve Cusack
 Director

European Institute of Women's Health Limited
RECONCILIATION OF MEMBERS' FUNDS

as at 30 June 2019

	Retained surplus	Total
	€	€
At 1 July 2017	135,947	135,947
Deficit for the financial year	<u>(14,935)</u>	<u>(14,935)</u>
At 30 June 2018	121,012	121,012
Deficit for the financial year	<u>(27,625)</u>	<u>(27,625)</u>
At 30 June 2019	<u>93,387</u>	<u>93,387</u>

European Institute of Women's Health Limited

CASH FLOW STATEMENT

for the financial year ended 30 June 2019

	Notes	2019 €	2018 €
Cash flows from operating activities			
Deficit for the financial year		(27,625)	(14,935)
		<u>(27,625)</u>	<u>(14,935)</u>
Movements in working capital:			
Movement in stocks		(48,623)	-
Movement in creditors		16,976	857
		<u>(59,272)</u>	<u>(14,078)</u>
Cash used in operations			
		<u>(59,272)</u>	<u>(14,078)</u>
Net decrease in cash and cash equivalents		(59,272)	(14,078)
Cash and cash equivalents at beginning of financial year		120,122	134,200
		<u>120,122</u>	<u>134,200</u>
Cash and cash equivalents at end of financial year	14	60,850	120,122
		<u><u>60,850</u></u>	<u><u>120,122</u></u>

European Institute of Women's Health Limited

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 30 June 2019

1. GENERAL INFORMATION

European Institute of Women's Health Limited is a company limited by guarantee incorporated in the Republic of Ireland. 33 Pearse Street, Dublin 2 is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 June 2019 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Income

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight line
----------------------------------	---	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

No charge to current or deferred taxation arises as the company has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, CHY number 12184.

European Institute of Women's Health Limited
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 30 June 2019

3. DEPARTURE FROM COMPANIES ACT 2014 PRESENTATION

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. GOING CONCERN

The company made a loss of €27,625, and has net assets of €93,387 at the year end.

During the first quarter of 2020, The Covid-19 pandemic has spread throughout Ireland and has effected all aspects of the Irish economy and seen many restrictions on the movement of people. The company has adapted accordingly and continues to operate. The directors have secured funding until June 2020 and continue to look for new project and funding opportunities. The directors are confident that there is sufficient resources to enable them to continue to operate for the foreseeable future. On that basis the financial statements are prepared on a going concern basis.

5. PROVISIONS AVAILABLE FOR AUDITS OF SMALL ENTITIES

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the Revenue and to assist with the preparation of the financial statements.

6. EMPLOYEES

The average monthly number of employees, including directors, during the financial year was 2, (2018 - 2).

	2019 Number	2018 Number
Adminstration	<u>2</u>	<u>2</u>

7. TANGIBLE FIXED ASSETS

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 July 2018	18,741	18,741
At 30 June 2019	<u>18,741</u>	<u>18,741</u>
Depreciation		
At 1 July 2018	18,741	18,741
At 30 June 2019	<u>18,741</u>	<u>18,741</u>
Net book value		
At 30 June 2019	<u>-</u>	<u>-</u>

8. STOCKS

	2019 €	2018 €
Work in progress	<u>60,000</u>	<u>11,377</u>

European Institute of Women's Health Limited
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 30 June 2019

9. CREDITORS	2019	2018
Amounts falling due within one year	€	€
Trade creditors	1,405	2,035
Taxation	11,046	5,992
Accruals	15,012	2,460
	<u>27,463</u>	<u>10,487</u>

10. STATUS

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 2.

11. CAPITAL COMMITMENTS

The company had no material capital commitments at the financial year-ended 30 June 2019.

12. CONTROLLING INTEREST

The company is controlled by the directors.

13. POST-BALANCE SHEET EVENTS

In the first half of 2020, the Covid-19 virus spread worldwide. In common with many other countries, the Irish government issued guidance and restrictions on the movement of people designed to slow the spread of this virus. The company put the necessary conditions in place to enable the company to continue to operate during this period. The directors are confident that the company will be fully operational once the period of restriction is lifted. There have been no significant events affecting the company since the financial year-end.

14. CASH AND CASH EQUIVALENTS	2019	2018
	€	€
Cash and bank balances	<u>60,850</u>	<u>120,122</u>

15. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on _____.

